Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: A clinical case with literature review

Journal of B.U.ON.

Volumn 11, Issue 4, 2006, Pages 523-527

  Piperkova, Elena ^a,c   Raphael, B ^b   Altinyay, M ^b   Castellon, I ^b   Libes, R ^b   Sandella, N ^b   Abdel Dayem, H ^b  

^a National Oncology Center Bulgaria   (Bulgaria)

^b ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^c NONE   (United States)

Author keywords

Computerized tomography; Positron emission tomography; Squamous cell anal cancer; Staging; Supraclavicular nodal metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; MITOMYCIN C; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ANUS CANCER; ARTICLE; CANCER LOCALIZATION; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONDYLOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RECTUM BIOPSY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; WHOLE BODY SCINTISCANNING; ANUS TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATIENT CARE; RADIOGRAPHY; SCINTISCANNING;

ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT CARE MANAGEMENT; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33947493390     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Cummings BJ. Metastatic anal cancer: The search for cure. Oncologie 2006; 29:5-6.
2. Greenlee RT, Muray T, Bolden S Wingo P. Cancer statistics 2000. CA Cancer J Clin 2000; 50:7-33.
3. Hwang HJ, Bestani C, Jimenez R et al. Treatment of patients with squamous cell carcinoma of the anal canal in the last 20 years in a gastroenterology hospital. Acta Gastroenterol Latinoam 2005; 35: 94-98.
4. Gervasoni JE, Wanebo HJ. Cancers of the anal canal and anal margin. Cancer Invest 2003; 21:452-464.
5. Stadler RF, Gregorcyk SG, Euhus DM, Place RJ, Huber PJ, Simmang CL. Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy. Dis Colon Rectum. 2004; 47: 1305-1309.
6. Ryan DP, Compton CC, Mater RJ. Carcinoma of the anal cancer. N Engl J Med 2000; 342:792-800.
7. Bartelink H, Roelofson F, Eschwege F et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer:results of a phase III randomized trial of the EORTC radiotherapy and gastrointestinal cooperative groups. J Clin Oncol 1997; 15:2040-2049.
8. Dzik-Jurasz AS. Pelvic malignancy: integrating form and function. Br J Radiol 2005; 78:86-93.
9. Weber WA. PET for response assessment in oncology: radiotherapy and chemotherapy. Br J Radiol 2005; 28 (Suppl):42-49.
10. Ell PJ. PET/CT in oncology: a major technology for cancer care. Chang Gung Med J 2005; 28: 274-283.
11. Meta J, Seltzer M, Schiepers C et al. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. J Nucl Med 2001; 42:586-590.
12. Johnson LG, Madeleine MM, Newcomer LM Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004; 101:81-88.
13. Deniaud-Alexandre E, Touboul E, Tiret E et al. Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal. Int J Radiat Oncol Biol Phys 2003; 56:1259-1273.
14. Klas JV, Rothenberger DA, Wong WD, Madoff RD. Malignant tumors of the anal canal: the spectrum of disease, treatment and outcomes. Cancer 1999; 85:1686-1693.
15. Hung A, Crane C, Delclos M et al. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer 2003; 97:1195-1202.
16. Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North Am 2001; 39: 883-917.
17. Adams S, Baum RP, Stuckensen T, Bitter K, Hor G. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med Mol Imaging 1998; 25:1255-1260.
18. Kalff V, Hicks RJ, Ware RE, Hogg A, Binns D, McKenzie AF. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 2002; 43: 492-499.